Skip to main content
Have a personal or library account? Click to login
Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: a randomized control study Cover

Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: a randomized control study

Radiology and Oncology
Volume 49 (2015): Issue 4 (December 2015)
By: ,   and    
Open Access
|Nov 2015
References

References

  1. 1. As toul P. Pleurodesis for recurrent malignant pleural effusions: the quest for the Holy Grail. [Editorial].2011;277-9.
    Open DOISearch in Google Scholar
  2. 2. Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review.2006;829-38.
    Open DOISearch in Google Scholar
  3. 3. Debeljak A, Kecelj P, Triller N, Letonja S, Kern I, Debevec L, et al. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions.2006;463-7.
    Search in Google Scholar
  4. 4. Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy of thoracoscopic machanical pleurodesis in patients with brest carcinoma.2004;432-6.
    Open DOISearch in Google Scholar
  5. 5. Mitchell RN, Cotran RS. Tissue repair: cell regeneration and fibrosis. In: Kumar V, Cotran RS, Robbins SL, editors.. 7th edition. Philadelphia: Saunders; 2003. p. 61-78.
    Search in Google Scholar
  6. 6. Lorenz PH, Longaker MT. Wounds: biology, pathology, and management. In: Norton JA, Barie PS, Bollinger RR, Chang AE, Lowry SF, Mulvihill SJ, et al, editors.2nd edition. New York: Springer; 2008. p. 191-208.
    Search in Google Scholar
  7. 7. Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing.2009;153-62.
    Open DOISearch in Google Scholar
  8. 8. Midwood KS, Valenick Williams L, Schwarzbauer JE. Tissue repair and the dynamics of the extracellular matrix.2004;1031-37.
    Open DOISearch in Google Scholar
  9. 9. Noncollagen components of the extracellular matrix. In: Lodish H, Berk A, editors.. 4th edition. New York: W. H. Freeman; 2000. p. 985-93.
    Search in Google Scholar
  10. 10. Antony VB, Nasreen N, Mohammed KA, Sriram PS, Frank W, Schoenfeld N, et al. Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis.2004;1522-8.
    Open DOISearch in Google Scholar
  11. 11. Teixeira LR, Vargas FS, Acencio MMP, Sabrina C. Ribeiro SC, Sales RKB, et al. Blockage of vascular endothelial growth factor (VEGF) reduces experimental Pleurodesis.2011;392-5.
    Open DOISearch in Google Scholar
  12. 12. Gary Lee YC, Teixeira LR, Devin CJ, Vaz MAC, Vargas FS, Thompson PJ, et al. Transforming growth factor-β2 induces pleurodesis significantly faster than talc.2001;640-4.
    Open DOISearch in Google Scholar
  13. 13. Duysinx BC, Corhay JL, Hubin L, Nguyen D, Henket M, Louis R. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions.2008;1708-14.
    Open DOISearch in Google Scholar
  14. 14. Genofre EH, Vargas FS, Acencio MMP, Antonangelo L, Teixeira LR, Marchi E. Talc pleurodesis: evidence of systemic inflammatory response to small size talc particles.2009;91-7.
    Open DOISearch in Google Scholar
  15. 15. Thickett DR, Armstrong L, Christie SJ, Millar AB. Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome.2001;1601-5.
    Open DOISearch in Google Scholar
  16. 16. Koenigsberg R, Maierhofer J, Steininger Tanja, Kienzer, G, Dittrich C. Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab.2014;184-8.
    Open DOISearch in Google Scholar
  17. 17. Hooper CE, Elversb KT, Welshc GI, Millard AB, Maskell NA. VEGF and sVEGFR-1 in malignant pleural effusions: Association with survival and pleurodesis outcomes.2012;443-9.
    Open DOISearch in Google Scholar
  18. 18. Ishii H, Yazawab T, Satob H, Suzukib T, Ikedab M, Hayashia Y, et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs).2004;325-37.
    Open DOISearch in Google Scholar
  19. 19. Mercurio AM, Lipscomb EA, Bachelder RE. Non-angiogenic functions of VEGF in breast cancer.2005;283-90.
    Open DOISearch in Google Scholar
  20. 20. Auer J, Keller U, Schmidt M, Ott O, Fietkau R, Distel LV. Individual radiosensitivity in a breast cancer collective is changed with the patients’ age.2014;80-6.
    Open DOISearch in Google Scholar
  21. 21. Kovač V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer.2004;334-40.
    Search in Google Scholar
  22. 22. Tuzi A, Lombardi D, Crivellari D, Militello L, Perin T, La Grassa M. Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies.2013;57-62.
    Open DOISearch in Google Scholar
  23. 23. Debevec L, Erzen J, Debeljak A, Crnjac A, Kovac V. Exploratory thoracotomy and its influence on the survival of patients with lung cancer.2006;479-84.
    Open DOISearch in Google Scholar
  24. 24. Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, Vrankar M. A phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for malignant pleural mesothelioma.2012;2308-8.
    Open DOISearch in Google Scholar
  25. 25. Klecka ME, Maldonado F. Symptom relief after large-volume thoracentesis in the absence of lung perfusion.2014;1141-3.
    Open DOISearch in Google Scholar
  26. 26. Crnjac A. The significance of thoracoscopic mechanical pleurodesis for the treatment of malignant pleural effusions.2004;28-32.
    Search in Google Scholar
  27. 27. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology.1993;365-76.
    Open DOISearch in Google Scholar
  28. 28. Light RW. What I have learned in the past 40 Years.2013;: xi.
    Open DOISearch in Google Scholar
  29. 29. Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, Putnam JB, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.1999;3364-8.
    Search in Google Scholar
  30. 30. Teixeira LR, Vargas FS, Acencio MMP, Antonangelo L, Novaes NP, Costa JD, et al. Influence of parecoxib (cox-2 inhibitor) in experimental pleurodesis.2009;595-600.
    Open DOISearch in Google Scholar
  31. 31. Zahid I, Routledge T, Bille A, Scarci M. What is the best treatment for malignant pleural effusions?2011;818-23.
    Search in Google Scholar
  32. 32. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β – an excellent servant but a bad master.2012;18 3.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.1515/raon-2015-0002 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 386 - 394
Submitted on: Oct 16, 2014
Accepted on: Nov 12, 2014
Published on: Nov 27, 2015
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
malignant pleural effusion,
pleurodesis,
growth factors,
quality of life
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2015 Aljaz Hojski, Maja Leitgeb, Anton Crnjac, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 49 (2015): Issue 4 (December 2015)
Previous article
Next article